[1] ALBERS J W, POP-BUSUI R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes [J]. Curr Neurol Neurosci Rep, 2014, 14(8): 473.
[2] LU B, YANG Z, WANG M, et al. High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown [J]. Diabetes Res Clin Pract, 2010, 88(3): 289-94.
[3] SUGIMOTO K, MURAKAWA Y, SIMA A A. Diabetic neuropathy--a continuing enigma [J]. Diabetes Metab Res Rev, 2000, 16(6): 408-33.
[4] TESFAYE S, CHATURVEDI N, EATON S E, et al. Vascular risk factors and diabetic neuropathy [J]. N Engl J Med, 2005, 352(4): 341-50.
[5] ZIEGLER D, RATHMANN W, DICKHAUS T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3 [J]. Diabetes care, 2008, 31(3): 464-9.
[6] YANG J, YAN P J, WAN Q, et al. Association between Hemoglobin Levels and Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes: A Cross-Sectional Study Using Electronic Health Records [J]. Journal of diabetes research, 2017, 2017(2835981.
[7] WU F, JING Y, TANG X, et al. Anemia: an independent risk factor of diabetic peripheral neuropathy in type 2 diabetic patients [J]. Acta Diabetol, 2017, 54(10): 925-31.
[8] JAISWAL M, DIVERS J, DABELEA D, et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study [J]. Diabetes care, 2017, 40(9): 1226-32.
[9] SU J B, ZHAO L H, ZHANG X L, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients [J]. Cardiovasc Diabetol, 2018, 17(1): 47.
[10] PERKINS B, BRIL V. Electrophysiologic testing in diabetic neuropathy [J]. Handb Clin Neurol, 2014, 126(235-48.
[11] KANE N M, OWARE A. Nerve conduction and electromyography studies [J]. J Neurol, 2012, 259(7): 1502-8.
[12] THIERRY, ARTZNER, BAPTISTE, et al. Liver transplantation for critically ill cirrhotic patients: Overview and pragmatic proposals [J].
[13] CHAPLIN S. Chronic heart failure in adults: diagnosis and management. [J]. Prescriber, 2019, 30(1): 16-8.
[14] SIEMS W G, SOMMERBURG O, GRUNE T. Erythrocyte free radical and energy metabolism [J]. Clin Nephrol, 2000, 53(1 Suppl): S9-17.
[15] JAVED S, ALAM U, MALIK R A. Burning through the pain: treatments for diabetic neuropathy [J]. Diabetes Obes Metab, 2015, 17(12): 1115-25.
[16] POPEL A S, JOHNSON P C. Microcirculation and Hemorheology [J]. Annu Rev Fluid Mech, 2005, 37(43-69.
[17] KIM E S, LEE S W, MO E Y, et al. Inverse association between serum total bilirubin levels and diabetic peripheral neuropathy in patients with type 2 diabetes [J]. Endocrine, 2015, 50(2): 405-12.
[18] CHUNG J O, CHO D H, CHUNG D J, et al. Physiological serum bilirubin concentrations are inversely associated with the prevalence of cardiovascular autonomic neuropathy in patients with Type 2 diabetes [J]. Diabet Med, 2014, 31(2): 185-91.
[19] REEDER B, WILSON M. Hemoglobin and Myoglobin Associated Oxidative Stress: from Molecular Mechanisms to Disease States [J]. Current Medicinal Chemistry, 12(23): 2741-51.
[20] LI Q R, WANG Z, ZHOU W, et al. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway [J]. Neural Regen Res, 2016, 11(2): 345-51.
[21] ROBERTO B, BELGIN B, MICHAEL B, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy [J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(3): 823-8.
[22] ENGLISH E, IDRIS I, SMITH G, et al. The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review [J]. Diabetologia, 2015, 58(7): 1409-21.
[23] GALLAGHER E J, LE ROITH D, BLOOMGARDEN Z. Review of hemoglobin A(1c) in the management of diabetes [J]. J Diabetes, 2009, 1(1): 9-17.
[24] THOMAS M, TSALAMANDRIS C, MACISAAC R, et al. Anaemia in diabetes: an emerging complication of microvascular disease [J]. Curr Diabetes Rev, 2005, 1(1): 107-26.
[25] ISMAIL-BEIGI F, CRAVEN T, BANERJI M A, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial [J]. Lancet, 2010, 376(9739): 419-30.